Reply #9: Amercian College of Pediatricians statement

[Celebration]

http://acpeds.org/?CONTEXT=art&cat=10006&art=140&BISKIT=2170483

Currently, an HPV vaccine is approved for children and adults ages 9-26. Despite encouraging results in prelicensure studies, research definitively establishing the duration of HPV vaccine protection, degree of protection and spectrum of side effects remain to be determined.

This was a 2007 statement. Has their position changed?

Apparently it was only tested in 1,121 girls under 15, yet that is who they are vaccinating. What was the reason for that? Why would testing be done mainly on a population that is not targeted for treatment?

I can't think of a good reason why the aluminum adjuvant was the only "placebo" studied. Has the safety of the adjuvant been the subject of FDA safety trials?

http://www.medscape.com/viewarticle/565691_3

During the last 15 years, a syndrome called macrophagic myofasciitis has been associated with aluminum-adjuvanted vaccines. Most cases have been reported in France and most of the patients have been adults,<32> but there are also descriptions of cases in other countries and in children.<33> The patients have presented with a variety of clinical symptoms, but usually they include myalgias, arthralgias, fatigue and, in some cases, serious neurological diseases, such as MS. Muscular biopsies have, in several cases, been taken from the deltoid region because of the symptoms. The biopsies have shown macrophages surrounding the muscle fibers forming a characteristic histological lesion. Electron microscopy has shown the presence of aluminum hydroxide inclusions in the lesions.<34> The patients have all been vaccinated with different aluminum-containing vaccines from months to years before the biopsy was taken.